Comparison of the indocyanine green fluorescence and blue dye methods in detection of sentinel lymph nodes in early-stage breast cancer

Annals of Surgical Oncology

Volumn 20, Issue 7, 2013, Pages 2213-2218

  Sugie, Tomoharu ^a   Sawada, Terumasa ^b   Tagaya, Nobumi ^c   Kinoshita, Takayuki ^d   Yamagami, Kazuhiko ^e   Suwa, Hirofumi ^f   Ikeda, Takafumi ^g   Yoshimura, Kenichi ^g   Niimi, Miyuki ^g   Shimizu, Akira ^g   Toi, Masakazu ^a  

^a KYOTO UNIVERSITY   (Japan)

^b SHOWA UNIVERSITY   (Japan)

^c DOKKYO MEDICAL UNIVERSITY   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e Shinko Hospital   (Japan)

^f Hyogo Prefectural Tsukaguchi Hospital   (Japan)

^g KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVANS BLUE; INDIGO CARMINE; INDOCYANINE GREEN;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BODY MASS; BREAST AREOLA; BREAST CANCER; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SIZE; CONTROLLED STUDY; EARLY CANCER; FEMALE; FLUORESCENCE ANALYSIS; GROUPS BY AGE; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIMARY TUMOR; PROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; SENTINEL LYMPH NODE METASTASIS;

ADULT; AGED; AXILLA; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; COLORING AGENTS; FEMALE; FLUORESCENCE; HUMANS; INDIGO CARMINE; INDOCYANINE GREEN; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; SENTINEL LYMPH NODE BIOPSY;

EID: 84878848362     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-2890-0     Document Type: Article

References (32)

1. Schrenk P, Rieger R, Shamiyeh A, et al. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer. 2000;88:608-14. (Pubitemid 30056936)
2. Giuliano AE, Haigh PI, Brennan MB, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol. 2000;18:2553-9. (Pubitemid 30432521)
3. Purushotham AD, Upponi S, Klevesath MB, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol. 2005;23:4312-21. (Pubitemid 46209968)
4. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392-9.
5. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546-53. (Pubitemid 36951366)
6. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomized phase 3 trial. Lancet Oncol. 2010;11:927-33.
7. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006;98:599-609. (Pubitemid 43904843)
8. Krag DN, Weaver DL, Alex JC, et al. Surgical resection and radio-localization of the sentinel node in breast cancer using a gamma probe. Surg Oncol. 1993;2:335-40. (Pubitemid 24019852)
9. Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391-401. (Pubitemid 24313232)
10. McMasters KM, Tuttle TM, Carlson DJ, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique in used. J Clin Oncol. 2000;18:2560-6. (Pubitemid 30432522)
11. Cody HS 3rd, Fey J, Akhurst T, et al. Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures. Ann Surg Oncol. 2001;18:2560-6.
12. Tafra L, Lannin DR, Swanson MS, et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg. 2001;233:51-9. (Pubitemid 32042775)
13. Kin T, Guiliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma. Cancer. 2006;106:4-16. (Pubitemid 43033320)
14. Morrow M, Rademaker AW, Bethke KP, et al. Learning sentinel node biopsy: results of a prospective randomized trial of two techniques. Surgery. 1999;126:714-20. (Pubitemid 29473174)
15. Kitai T, Inomoto T, Miwa M, Shikayama T. Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer. Breast Cancer. 2005;12:211-5.
16. Tagaya N, Yamazaki R, Nakagawa A, et al. Intraoperative identification of sentinel lymph nodes by near-infrared fluorescence imaging inpatients with breast cancer. Am J Surg. 2008;195:850-3. (Pubitemid 351749448)
17. Sugie T, Kassim KA, Takeuchi M, et al. A novel method for sentinel lymph node biopsy by indocyanine green fluorescence technique in breast cancer. Cancers. 2010;2:713-20.
18. Hojo T, Nagao T, Kikuyama M, et al. Evaluation of sentinel node biopsy by combined fluorescent and dye method and lymph flow for breast cancer. Breast. 2010;19:210-3.
19. Hishch C, Murawa D, Mohr Z, et al. ICG fluorescence-guided sentinel node biopsy for axillary nodal staging in breast cancer. Breast Cancer Res Treat. 2010;121:373-8.
20. Motomura K, Inaji H, Komoike Y, et al. Sentinel node biopsy guided by indocyanine green dye in breast cancer patients. Jpn J Clin Oncol. 1999;29:604-7.
21. Anderson GL, Neuhouser ML. Obesity and the risk for premenopausal and postmenopausal breast cancer. Cancer Prev Res (Phila). 2012;5:515-21.
22. Healy LA, Ryan AM, Rowley S, et al. Obesity increases the risk of postmenopausal breast cancer and is associated with more advanced stage at presentation but no impact on survival. Breast J. 2010;16:95-7.
23. Cox CE, Dupont E, Whitehead GF, et al. Age and body mass index may increase the chance of failure in sentinel lymph node biopsy for women with breast cancer. Breast J. 2002;8:88-91. (Pubitemid 34233586)
24. Hughes M, Goffman TG, Perry RR, et al. Obesity and lymphatic mapping with sentinel lymph node biopsy in breast cancer. Am J Surg. 2004;187:52-7. (Pubitemid 38054355)
25. Abe H, Umeda T, Mori M, et al. Indocyanine green fluorescence imaging system for sentinel lymph node biopsy in early breast cancer patients. J Clin Oncol. 2010;28(Suppl. 15):6492.
26. Kitai T, Kawashima M. Transcutaneous detection and direct approach to the sentinel node using axillary compression technique in ICG fluorescence- navigated sentinel node biopsy for breast cancer. Breast Cancer. 2012;19:343-8.
27. Zakaria S, Degnim AC, Kleer CG, et al. Sentinel lymph node biopsy for breast cancer: how many nodes are enough? J Surg Oncol. 2007;96:554-9. (Pubitemid 350191479)
28. Toi M, Winer EP, Inamoto T, et al. Identifying gaps in the locoregional management of early breast cancer: highlights from the Kyoto Consensus Conference. Ann Surg Oncol. 2011;18:2885-92.
29. Ban EJ, Lee JS, Koo JS, et al. How many sentinel lymph nodes are enough for accurate axillary staging in t1-2 breast cancer? J Breast Cancer. 2011;14:296-300.
30. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569-75.
31. Murawa D, Hirche C, Dresel S, et al. Sentinel lymph node biopsy in breast cancer guided by indocyanine green fluorescence. Br J Surg. 2009;96:1289-94.
32. Wishart GC, Loh SW, Jones L, et al. A feasibility study (ICG-10) of indocyanine green (ICG) fluorescence mapping for sentinel lymph node detection in early breast cancer. Eur J Surg Oncol. 2012;38:651-6.